The historical rank and industry rank for Endonovo Therapeutics's Net Margin % or its related term are showing as below:
ENDV'
s Net Margin % Range Over the Past 10 Years
Min: -169150 Med: -4919.45 Max: 4946.43
Current: -38333.33
ENDV's Net Margin % is ranked worse than 95.7% of 1001
companies
in the Biotechnology industry
Industry Median: -132.46
vs ENDV: -38333.33
Endonovo Therapeutics Net Margin % Historical Data
The historical data trend for Endonovo Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Endonovo Therapeutics's Net Margin %
For the Biotechnology subindustry, Endonovo Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Endonovo Therapeutics's Net Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Endonovo Therapeutics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Endonovo Therapeutics (OTCPK:ENDV) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Endonovo Therapeutics Net Margin % Related Terms
Thank you for viewing the detailed overview of Endonovo Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Endonovo Therapeutics Inc is an USA-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENDV has been successfully added to your 